Neuroblastoma
📧 Sign up to get email alerts when something new happens for Neuroblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas [Phase 1, Phase 2]
Clinical trial update reports ongoing Phase 1/Phase 2 testing of eflornithine (DFMO) with AMXT 1501 for neuroblastoma, CNS tumors, and sarco…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Clinical trial update notes an expanded access protocol for 131I-MIBG therapy in refractory neuroblastoma, with conditions including childho…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) [Phase 1, Phase 2]
Substudy 01A of MK-9999-01A (LIGHTBEAM-U01) evaluates Zilovertamab Vedotin in pediatric and young adult participants with hematologic malign…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) [Phase 2]
This update reports on a Phase 2 pediatric MATCH trial evaluating ensartinib for patients with relapsed or refractory ALK- or ROS1-genomic a…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma [Phase 1]
Phase 1 clinical trial investigating lenalidomide and dinutuximab with or without isotretinoin in younger patients with refractory or recurr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors [Phase 1, Phase 2]
Clinical trial evaluating silmitasertib (CX-4945) in combination with chemotherapy for relapsed or refractory solid tumors; Phase 1 and Phas…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma [Phase 1]
Phase I clinical trial update for ThINKK Adoptive Immunotherapy after allogeneic hematopoietic stem cell transplantation in children with ac…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
This clinical trial update reports on using serial ctDNA and molecular residual disease monitoring to assess disease burden in neuroblastoma…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN [Phase 1]
Phase 1 clinical trial evaluating a third-generation GD-2 CAR-T cell therapy with an iCaspase suicide safety switch for neuroblastoma; curre…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Open-Label Study of 18F-mFBG for Imaging Neuroblastoma [Phase 3]
Open-label Phase 3 clinical trial evaluating 18F-mFBG imaging for neuroblastoma; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma [Phase 2]
Phase 2 clinical trial update for a neuroblastoma vaccine combined with beta-glucan; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma [Phase 2]
A Phase 2 clinical trial evaluating iodine-131 labeled metaiodobenzylguanidine (MIBG) in patients with recurrent or refractory neuroblastoma…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors [EARLY_Phase 1]
A Mayo Clinic-sponsored early-phase 1 trial is evaluating 68Ga-DOTATATE PET/CT as a diagnostic tool for pediatric metastatic neuroendocrine …
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma [Phase 1, Phase 2]
This clinical trial update indicates a Phase 1/2 study of dual-target GD2/B7-H3 CAR-NK cells for pediatric relapsed or refractory neuroblast…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma [Phase 1]
Phase 1 clinical trial evaluating GD2-targeted CAR T-cells engineered with IL-15 and inducible caspase-9 for relapsed/refractory neuroblasto…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 pediatric MATCH trial evaluating IDH1-mutant tumors for response to ivosidenib; results for recurrent and refractory solid tumors, l…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial [Phase 2]
A Phase II clinical trial (NANT 2021-01) evaluating sequential Temozolomide, Irinotecan, NK cell therapy, and a GD2 monoclonal antibody for …
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells [Phase 1]
Phase 1 trial evaluating expanded natural killer (NK) cell immunotherapy for relapsed or refractory neuroblastoma, sponsored by the New Appr…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Neuroblastoma Biology Study
A neuroblastoma biology study led by the New Approaches to Neuroblastoma Therapy Consortium is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma [Phase 1]
A Phase 1 trial evaluating sorafenib in combination with cyclophosphamide/topotecan for relapsed and refractory neuroblastoma; the study sta…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Neuroblastoma Precision Trial
Clinical trial status update for the Neuroblastoma Precision Trial, sponsored by New Approaches to Neuroblastoma Therapy Consortium; the stu…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma [Phase 2]
This clinical trial update describes a Phase 2 study comparing 123I-MIBG and 18F-MFBG imaging in patients with newly diagnosed, high-risk ne…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas [Phase 1]
Phase 1 dose-escalation study of CLR-131 in children with relapsed or refractory malignant tumors, including neuroblastoma and sarcomas, cur…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma [Phase 2]
Phase 2 clinical trial evaluating a vaccine in combination with beta-glucan and GM-CSF in neuroblastoma patients, currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating alpha/beta T and B cell depletion with zoledronic acid for solid tumors; recruitment is ongoing.